Sulindac sulfide is a potent, reversible and noncompetitive inhibitor of γ42-secretase with an IC50 of 20.2 μM. It preferentially reduces Aβ42 generation, inhibits Aβ40 and Notch intracellular domain production, and can be used in Alzheimer’s disease research.

Sulindac sulfide is a potent, reversible and noncompetitive inhibitor of γ42-secretase with an IC50 of 20.2 μM. It preferentially reduces Aβ42 generation, inhibits Aβ40 and Notch intracellular domain production, and can be used in Alzheimer’s disease research.

Sulindac sulfide is a potent, reversible and noncompetitive inhibitor of γ42-secretase with an IC50 of 20.2 μM. It preferentially reduces Aβ42 generation, inhibits Aβ40 and Notch intracellular domain production, and can be used in Alzheimer’s disease research.

VRK-IN-1 is a potent and selective inhibitor of vaccinia-related kinase 1 (VRK1) with an IC50 of approximately 150 nM. It also facilitates H4 deacetylation (reducing H4K16 acetylation) and promotes the accumulation of DNA strand breaks while preventing progression of the DNA repair process.

VRK-IN-1 is a potent and selective inhibitor of vaccinia-related kinase 1 (VRK1) with an IC50 of approximately 150 nM. It also facilitates H4 deacetylation (reducing H4K16 acetylation) and promotes the accumulation of DNA strand breaks while preventing progression of the DNA repair process.

VRK-IN-1 is a potent and selective inhibitor of vaccinia-related kinase 1 (VRK1) with an IC50 of approximately 150 nM. It also facilitates H4 deacetylation (reducing H4K16 acetylation) and promotes the accumulation of DNA strand breaks while preventing progression of the DNA repair process.

VRK-IN-1 is a potent and selective inhibitor of vaccinia-related kinase 1 (VRK1) with an IC50 of approximately 150 nM. It also facilitates H4 deacetylation (reducing H4K16 acetylation) and promotes the accumulation of DNA strand breaks while preventing progression of the DNA repair process.

MDL12330A is an inhibitor of adenylyl cyclase that blocks vasopressin-induced short-circuit current (SCC). It also inhibits cAMP phosphodiesterase, which may mask its effect on adenylyl cyclase.

MDL12330A is an inhibitor of adenylyl cyclase that blocks vasopressin-induced short-circuit current (SCC). It also inhibits cAMP phosphodiesterase, which may mask its effect on adenylyl cyclase.

MDL12330A is an inhibitor of adenylyl cyclase that blocks vasopressin-induced short-circuit current (SCC). It also inhibits cAMP phosphodiesterase, which may mask its effect on adenylyl cyclase.